Skip to main content

CalAmp Corp Value Stock - Dividend - Research Selection

Calamp

ISIN: US1281261099 , WKN: A0B7RX

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

CalAmp Corp. provides Internet of Things (IoT) enablement solutions for various mobile and fixed applications worldwide. The company provides solutions for mobile resource management and applications for the IoT market, which enable customers in the transportation, government, construction, automotive, and energy markets to optimize their operations by collecting, monitoring, and reporting business-critical data and desired intelligence from remote and mobile assets. It also offers a portfolio of wireless communications products, such as asset tracking devices, mobile telemetry units, fixed and mobile wireless gateways, and multi-mode wireless routers; and cloud-based telematics software-as-a-service and platform-as-a-service applications. The company sells its products and services through direct and indirect sales channels in the United States, as well as through sales personnel in Latin America, the Middle East, and Europe. CalAmp Corp. was founded in 1981 and is headquartered in Irvine, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-01-16
CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on January 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a n

Camp4 Therapeutics Corporation (CAMP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-14
Camp4 Therapeutics Corporation (CAMP) 44th Annual J.P.

CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why

2026-01-13
CAMP4 Therapeutics Corporation (CAMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-06
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conf

Getty Images, Torm, and More Stocks See Action From Activist Investors

2026-01-02
Activists also report to the SEC on Vor Biopharma, Camp4 Therapeutics, and Recursion Pharmaceuticals.

GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst

2025-12-19
CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 clinical milestones.

Novo files for CagriSema approval; Merck and Pfizer’s trial win

2025-12-19
Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock

2025-12-18
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the pricing of its underwritten offering of 5,000,000 shares of its common stock at a price of $6.00 per share. The gro

CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries

2025-12-18
Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments, in addition to tiered royalties CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targetin

UPDATE: CAMP4 Therapeutics Partners With GSK To Develop ASO Therapies For Neurodegenerative And Renal Diseases; Secures $17.5M Upfront

2025-12-18
Collaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseasesCAMP4 to receive $17.5 million upfront and eligible for